The first new Class 4 "iodine xalol injection" was approved for market.

On August 17th, Spiri new class 4 generic iodine keshaol injections were approved for listing by the State Drug Administration, as the first manufacturer in China to pass the consistency evaluation of the variety through consistency evaluation.
iodide keshaol injection is an X-ray imaging agent used in adults for cardiovascular imaging, cerebroan angiology, peri-arterial angiology, abdominal angiology, urinary tract imaging, intravenous imaging, and CT-enhanced examination;
currently, there are General Electric, Beiland Pharmaceuticals, Hengrui, Yangzijiang and Nanjing Zhengtianqing 5 enterprises approved for listing, but no enterprises have passed the consistency evaluation.
2017, global sales of iodocosol injections were approximately $489 million, in Europe about $135 million and in China about $173 million, according to the IMS database.
Staly has already passed the consistency evaluation of three modeling agent varieties by 2020, in addition to the approved iodine keshaol injections, as well as iodine sea alcohol injections and iodine parol injections, according to the new category 4 submitted for listing applications are in the "under review" phase of iodine alcohol injections and iodine Mepoor injections.
.